CA-BRAIN-CORP
9.11.2021 13:02:03 CET | Business Wire | Press release
Brain Corp , an artificial intelligence (AI) company creating transformative core technology in robotics, today announced that its BrainOS®-powered fleet of autonomous mobile robots have officially reached 100 billion square feet of coverage. In doing so, 6.8 million hours have been given back to employees and operations managers, allowing them to focus on customer experience and other high-value tasks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005781/en/
“We are thrilled to celebrate reaching 100 billion square feet of coverage with our fleet which represents the square footage of the entire commercial space in the United States,” said Eugene Izhikevich, CEO and Founder of Brain Corp. “The milestone represents a clear success of deploying autonomous robots at scale and across multiple industries. As a company committed to continuous improvement, it’s been incredibly gratifying to see such major advances in our fleet’s performance, even as it has been scaled and expanded to operate in multiple new dynamic public environments across the world.”
From October 1, 2020, to October 1, 2021, usage of automated robotics increased across a number of industry sectors with several seeing dramatic year-over-year growth. Increases in square feet covered autonomously within sectors include:
- Retail +40%
- Airports +69%
- Malls +113%
- Education +426%
- Hospitals +2,500%
While Brain Corp’s initial robot fleet growth was centered around retail environments, the significant increases in deployments within other sectors including malls, educational facilities, and hospitals, reflects the ability of BrainOS®-powered robots to learn the key dynamics of new environments, a critical factor in the ongoing advancement of its technology.
Creating AI software to power autonomous robots operating in new, varying environments requires advanced software and sensors that ensure high levels of performance and safety, all while prioritizing security and data protection. BrainOS®-powered robots align with all applicable privacy regulations, processing data exclusively for navigation and operational support without any additional data sources which could identify a natural person.
“As we’ve expanded our fleet size, our focus has always been on safely operating in a variety of different environments,” said Sean Felker, Lead Functional Safety Engineer. “Reaching 100 billion square feet of autonomous coverage is validation that this focus is paying off. We have always been committed to helping customers become more efficient in their operations, and it's a testament to our skilled teams that this is being successfully achieved while prioritizing safety and privacy.”
“This is an exceptionally exciting time to be in the field of robotics and automation,” said Nick Whitney, SVP, Sales America. “Across numerous industries, leaders are reinventing how they operate by combining the data-driven sophistication of automated robots with human teams.”
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data to enable the digital transformation of physical workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 16,000 AMRs, representing the largest fleet of its kind in the world. For more information, visit www.braincorp.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005781/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom